Related Experiment Video
Updated: Oct 2, 2025

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
Interim outcomes of mechanical thrombectomy for deep vein thrombosis from the All-Comer CLOUT Registry
David J Dexter1, Herman Kado2, Jonathan Schor3
1Sentara Vascular Specialists, Norfolk, VA.
Insights
The ClotTriever System effectively removed thrombus in 86% of patients with lower extremity deep vein thrombosis (DVT). This all-comer study showed sustained clinical improvements and a favorable safety profile at six months.
Area of Science:
- Vascular Surgery
- Interventional Radiology
- Medical Device Technology
Background:
- Deep vein thrombosis (DVT) affects a significant patient population, with varying chronicity and treatment challenges.
- Current treatment options for DVT may have limitations, particularly in "all-comer" patient groups.
- The ClotTriever System offers a minimally invasive approach for mechanical thrombectomy.
Purpose of the Study:
- To assess the safety and effectiveness of the ClotTriever System in an all-comer population with lower extremity DVT.
- To evaluate thrombus removal rates, safety outcomes, and long-term clinical improvements.
- To analyze outcomes across a spectrum of thrombus chronicity.
Main Methods:
- Prospective, single-arm CLOUT registry study of 250 patients with lower extremity DVT.
- Inclusion of diverse patient profiles, including those with bilateral DVT, failed prior treatments, and varied symptom durations.
- Primary endpoint: complete or near-complete thrombus removal (≥75%) assessed by Marder scores; secondary endpoints: safety events and clinical outcomes (post-thrombotic syndrome, pain, quality of life) at 6 months.
Main Results:
- High effectiveness: 86% of limbs achieved complete or near-complete thrombus removal.
- Favorable safety: Only one device-related serious adverse event reported within 30 days.
- Significant clinical improvements: Sustained reductions in post-thrombotic syndrome (24% at 6 months), pain, and improved quality of life.
- Efficient procedure: Median thrombectomy time of 28 minutes, with 99.6% treated in a single session, and no patients requiring thrombolytics.
Conclusions:
- The CLOUT registry demonstrates the ClotTriever System's favorable safety and effectiveness in an all-comer DVT population.
- The system achieves high rates of thrombus removal across acute, subacute, and chronic DVT.
- Sustained clinical benefits and improvements in quality of life are observed at six months post-treatment.
Objectives:
The multicenter, prospective, single arm CLOUT registry assesses the safety and effectiveness of the ClotTriever System (Inari Medical, Irvine, CA) for the treatment of acute and nonacute lower extremity deep vein thrombosis (DVT) in all-comer patients. Reported here are the outcomes of the first 250 patients.
Methods:
All-comer patients with lower extremity DVT were enrolled, including those with bilateral DVT, those with previously failed DVT treatment, and regardless of symptom duration. The primary effectiveness end point is complete or near-complete (≥75%) thrombus removal determined by independent core laboratory-adjudicated Marder scores. Safety outcomes include serious adverse events through 30 days and clinical outcomes include post-thrombotic syndrome severity, symptoms, pain, and quality of life through 6 months.
Results:
The median age was 62 years and 40% of patients had contraindications to thrombolytics. A range of thrombus chronicity (33% acute, 35% subacute, 32% chronic) was observed. No patients received thrombolytics and 99.6% were treated in a single session. The median thrombectomy time was 28 minutes. The primary effectiveness end point was achieved in 86% of limbs. Through 30 days, one device-related serious adverse event occurred. At 6 months, 24% of patients had post-thrombotic syndrome. Significant and sustained improvements were observed in all clinical outcomes, including the Revised Venous Clinical Severity Score, the numeric pain rating scale, and the EuroQol Group 5-Dimension Self-Report Questionnaire.
Conclusions:
The 6-month outcomes from the all-comer CLOUT registry with a range of thrombus chronicities demonstrate favorable effectiveness, safety, and sustained clinical improvements.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Varicose Veins II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis I: Introduction
Venous Thrombosis IV: Nursing Management

